NO20082672L - Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon - Google Patents
Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjonInfo
- Publication number
- NO20082672L NO20082672L NO20082672A NO20082672A NO20082672L NO 20082672 L NO20082672 L NO 20082672L NO 20082672 A NO20082672 A NO 20082672A NO 20082672 A NO20082672 A NO 20082672A NO 20082672 L NO20082672 L NO 20082672L
- Authority
- NO
- Norway
- Prior art keywords
- hypertension
- treatment
- general
- systolic
- cycletanine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Denne oppfinnelsen tilveiebringer sammensetninger av cikletanin og andre furopyridiner for behandling av økt pulstrykk, isolert systolisk hypertensjon og generell hypertensjon, i monoterapeutiske former (kun furopyridin) og i sammensetninger kombinert med andre antihypertensive midler, kardiovaskulære midler, og/eller oral anti-diabetiske midler. Slike furopyridinsammensetninger inkluderer enantiomerisk rene (positive eller negative) utførelsesformer og ikke-racemiske enantiomerblandinger, og omfatter daglige doser på mindre enn 50 mg. Videre er det tilveiebrakt fremgangsmåter for behandling av generell eller systolisk hypertensjon, pasienter administreres med furopyridinsammensetninger alene eller i kombinasjon med et andre middel for behandling av generell hypertensjon eller systolisk hypertensjon og assosierte komplikasjoner.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73563205P | 2005-11-09 | 2005-11-09 | |
US75852406P | 2006-01-11 | 2006-01-11 | |
US11/356,158 US20070105817A1 (en) | 2005-11-09 | 2006-02-15 | Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension |
PCT/US2006/043487 WO2007056454A2 (en) | 2005-11-09 | 2006-11-07 | Use of cicletanine and other furopyridines for treatment of hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20082672L true NO20082672L (no) | 2008-07-21 |
Family
ID=38004571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20082672A NO20082672L (no) | 2005-11-09 | 2008-06-09 | Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070105817A1 (no) |
EP (1) | EP1951264A4 (no) |
AU (1) | AU2006311574A1 (no) |
CA (1) | CA2632931A1 (no) |
EA (1) | EA200801305A1 (no) |
HR (1) | HRP20080255A2 (no) |
IL (1) | IL192031A0 (no) |
NO (1) | NO20082672L (no) |
WO (1) | WO2007056454A2 (no) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE05810535T1 (de) * | 2004-10-18 | 2007-04-19 | Teva Pharmaceutical Industries Ltd. | Verfahren zur herstellung von amorphem atorvastatin-hemi-calcium durch lösen des salzes in einem organischen lösungsmittel, bei dem es sich um eine mischung enes alkohols und eines ketons und/oder eines esters handelt, und entfernen des lösungsmittels |
US10842813B2 (en) | 2007-02-26 | 2020-11-24 | Heartbeet Ltd | Compositions of nitrates and methods of use thereof |
US11759477B2 (en) | 2007-02-26 | 2023-09-19 | Heartbeet Ltd. | Compositions of nitrates and methods of use thereof |
HUE032165T2 (en) | 2011-04-13 | 2017-09-28 | Thermolife Int Llc | Methods of using N-actyl-beta-alanine |
WO2015103445A1 (en) * | 2013-12-31 | 2015-07-09 | Rockey Don C | Systems, methods, techniques, and compounds in research and treatment of portal hypertension and other conditions |
US11865139B2 (en) | 2020-11-12 | 2024-01-09 | Thermolife International, Llc | Method of treating migraines and headaches |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN156817B (no) * | 1981-02-10 | 1985-11-09 | Scras | |
GB8330658D0 (en) * | 1983-11-17 | 1983-12-29 | Scras | 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives |
GB8808001D0 (en) * | 1988-04-06 | 1988-05-05 | Scras | Stereospecific preparative process for furol(3,4-c)pyridine derivatives |
US5130252A (en) * | 1990-05-14 | 1992-07-14 | Synthetech, Inc. | Resolution of furopyridine enantiomers and synthetic precursors thereof |
TW201305B (no) * | 1991-04-03 | 1993-03-01 | Otsuka Pharma Co Ltd | |
LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
JPH09507075A (ja) * | 1993-12-23 | 1997-07-15 | メルク エンド カンパニー インコーポレーテッド | ロサルタンの多形とロサルタン▲ii▼形調製のための方法 |
US5582839A (en) * | 1995-04-18 | 1996-12-10 | Nutrition 21 | Magnesium taurate and other mineral taurates |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
WO2001035961A1 (en) * | 1999-10-29 | 2001-05-25 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
US6277860B1 (en) * | 1999-10-29 | 2001-08-21 | Pfizer Inc | Furopyridine antibacterials |
WO2002068439A1 (fr) * | 2001-02-26 | 2002-09-06 | Kissei Pharmaceutical Co., Ltd. | Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci |
CA2532807A1 (en) * | 2003-07-17 | 2005-02-03 | Cotherix, Inc. | Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome |
US20060089374A1 (en) * | 2003-07-17 | 2006-04-27 | Glenn Cornett | Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease |
WO2005021039A1 (en) * | 2003-08-29 | 2005-03-10 | Cotherix, Inc. | Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome |
US20050101608A1 (en) * | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
US20070141174A1 (en) * | 2005-01-13 | 2007-06-21 | Navitas Pharma, Inc. | Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension |
WO2006128035A2 (en) * | 2005-05-26 | 2006-11-30 | Navitas Pharma, Inc. | Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension |
-
2006
- 2006-02-15 US US11/356,158 patent/US20070105817A1/en not_active Abandoned
- 2006-11-07 EP EP06837155A patent/EP1951264A4/en not_active Ceased
- 2006-11-07 AU AU2006311574A patent/AU2006311574A1/en not_active Abandoned
- 2006-11-07 CA CA002632931A patent/CA2632931A1/en not_active Abandoned
- 2006-11-07 WO PCT/US2006/043487 patent/WO2007056454A2/en active Application Filing
- 2006-11-07 EA EA200801305A patent/EA200801305A1/ru unknown
-
2008
- 2008-06-09 NO NO20082672A patent/NO20082672L/no not_active Application Discontinuation
- 2008-06-10 HR HR20080255A patent/HRP20080255A2/xx not_active Application Discontinuation
- 2008-06-10 IL IL192031A patent/IL192031A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20070105817A1 (en) | 2007-05-10 |
IL192031A0 (en) | 2011-08-01 |
EP1951264A4 (en) | 2009-03-25 |
AU2006311574A1 (en) | 2007-05-18 |
EP1951264A2 (en) | 2008-08-06 |
CA2632931A1 (en) | 2007-05-18 |
WO2007056454A2 (en) | 2007-05-18 |
HRP20080255A2 (en) | 2008-11-30 |
EA200801305A1 (ru) | 2009-06-30 |
WO2007056454A3 (en) | 2007-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2248519A3 (en) | Non-mucoadhesive film dosage forms | |
RU2013111077A (ru) | Дипептидное пролекарство, его применение и лекарственное средство | |
MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
MXPA04004842A (es) | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. | |
IL161154A0 (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
NO20082672L (no) | Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon | |
CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
MXPA05004778A (es) | Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas. | |
SG146648A1 (en) | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | |
WO2007062413A3 (en) | Use of parp-1 inhibitors | |
AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
PL1778209T3 (pl) | Sposoby i kompozycje do doustnego dostarczania FTS | |
WO2008032222A3 (en) | Treatment of vertigo with acetyl-l-leucine | |
RS44304A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
WO2005055933A3 (en) | Treatment of psoriasis with rosiglitazone | |
HUP0402062A2 (hu) | Alkanoil-L-karnitin alkalmazása merevedési zavar kezelésére és ezt tartalmazó gyógyszerkészítmények | |
HK1075390A1 (en) | Citalopram for the treatment of elevated blood pressure | |
Lee | Delayed Occurrence of Maxillary Sinusitis after Simultaneous Maxillary Sinus Augmentation and Implant: A Case Report and Literature Review | |
MD2551G2 (ro) | Utilizarea soluţiilor ozonate acceptabile farmaceutic ozonate pentru tratamentul micozelor cavităţii bucale | |
UA101370C2 (ru) | Пероральные составы, которые содержат аналоги цитидина, и способы их использования | |
RU2007113591A (ru) | Способ лечения тромбоцитарных дисфункций у лиц, страдающих метаболическим синдромом | |
UA36576A (uk) | Спосіб корекції реактивності організму у хворих на інфаркт міокарда в гострому та підгострому періодах | |
UA86813C2 (ru) | Ингибиторы бета-гидроксистероидной дегидрогеназы типа 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |